Metabolic Disorders

According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval. 

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade. 

Investor Deerfield Management and genomic sequencing giant Illumina entered into a five-year partnership to identify novel targets and drug candidates that may be spun out into new companies.

Vertex expresses surprise at the US FDA’s call for a halt, as it reveals an exciting milestone reached - the first trial participant now producing their own insulin.

After months of manufacturing blunders, the Danish major’s obesity drug has shown its blockbuster potential in the first quarter but rival Eli Lilly could soon stoke up the competition.

Tirzepatide shows ability to produce a mean 52-pound weight loss at 72 weeks, setting up a market showdown with Novo’s Wegovy. Lilly’s quarterly call included reassurance about donanemab for Alzheimer’s and high growth for its COVID-19 antibody.

Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.

The company is targeting revenues of DKK25bn ($3.66bn) from Wegovy for obesity in 2025, with plans to amp up the US launch this year following an initial supply disruption.

The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.

INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.

Korean pharma firm poised to file for domestic approval of SGLT-2 inhibitor enavogliflozin after positive top-line Phase III data, marking progress for the country's first drug in the already crowded class. But will it be competitive?

The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.